RVPH — Reviva Pharmaceuticals Holdings,. Income Statement
0.000.00%
Last trade - 00:00
- $84.31m
- $60.95m
2019 February 28th | 2020 February 29th | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 8-K | 8-K |
Standards: | USG | USG | USG | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.153 | 0.725 | 10.1 | 28.2 | 39.5 |
Operating Profit | -0.153 | -0.725 | -10.1 | -28.2 | -39.5 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.574 | 0.618 | -8.52 | -28.2 | -39.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.574 | 0.618 | -8.52 | -28.3 | -39.3 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.574 | 0.618 | -8.52 | -28.3 | -39.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.574 | 0.618 | -8.52 | -28.3 | -39.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.281 | 0.237 | -0.576 | -1.45 | -1.65 |